The interim figures mark the point where CelLBxHealth PLC (AIM:CLBX, FRA:DWV) stops being a restructuring story and starts being a commercial one, says a note from Cavendish.
The heavy lifting is done. Operating expenses are down to £3.2 million from £10.1 million, the annualised cash cost base sits at about £6.3 million, and the operating loss has narrowed to £2.7 million from £9.7 million.
Crucially, that was achieved while absorbing £1.5 million of restructuring payments, so the underlying run rate is better than the headline suggests.
What replaces the cost story is early evidence that the partner-led model works.
Second-quarter revenue doubled over the first quarter, the first tangible sign that routing Parsortix through the platforms of QIAGEN, Roche Diagnostics, Illumina and Myriad reaches customers faster than selling alone ever did.
The AstraZeneca master services agreement and the AdventHealth studies give that reach institutional weight.
Cavendish, the company's broker, has left its forecasts untouched and reiterated a 'buy' rating with a 4p target, roughly three times the current price.
The £3.5 million weighted pipeline and a runway into the second quarter of 2027 give the incoming chief executive something rare at this end of the market: a lean cost base and time to sell into it.
